`Horniak, David
`Bill.Zimmerman
`RE: Narcan Nasal Spray -- IPR Request
`Wednesday, November 06, 2019 1:58:50 PM
`
`From:
`To:
`Cc:
`Subject:
`Date:
`
`David:
`
`Thank you for your email. The approach you outline below, using the default protective order, is
`acceptable to Indivior. Please contact me if you run into any issues.
`
`Sincerely,
`Bill
`
`Bill Zimmerman
`Partner
`Bill.Zimmerman@knobbe.com
`202-640-6404 Direct
`Knobbe Martens
`1717 Pennsylvania Ave. N.W., Ste. 900
`Washington, D.C. 20006
`www.knobbe.com/bill-zimmerman
`
`From: Horniak, David <DHorniak@wc.com>
`Sent: Wednesday, November 6, 2019 1:55 PM
`To: Bill.Zimmerman <Bill.Zimmerman@knobbe.com>
`Subject: RE: Narcan Nasal Spray -- IPR Request
`
`Hi Bill,
`
`Apologies for the delay in getting back to you. We agree to Indivior’s restrictions, and thank you for
`your consideration and prompt response. We have looked at the default PTAB protective order
`(which, as you probably know, is what the PTAB generally enters unless there is a good argument to
`do something different), and we believe it provides protections consistent with what you have
`described. If Indivior documents are filed under seal, which is how we will submit them, then
`subsequent use of the documents will have to occur in sealed proceedings, not in an open hearing.
`Accordingly, absent objection, we will proceed in this manner. Thanks again.
`
`Best,
`
`David
`
`David Horniak
`Williams & Connolly LLP
`725 Twelfth Street, N.W., Washington, DC 20005
`(P) 202-434-5852 | (F) 202-434-5029
`
`Opiant Exhibit 2178
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 1
`
`
`
`dhorniak@wc.com | www.wc.com/dhorniak
`
`From: Bill.Zimmerman <Bill.Zimmerman@knobbe.com>
`Sent: Tuesday, October 22, 2019 3:02 PM
`To: Horniak, David <DHorniak@wc.com>
`Cc: Bill.Zimmerman <Bill.Zimmerman@knobbe.com>
`Subject: RE: Narcan Nasal Spray -- IPR Request
`
`Dear David:
`
`Thank you for your email. Indivior will consent to the use of the documents attached to your email
`in the IPR proceedings, provided that the documents are submitted under seal pursuant to a
`protective order in the IPR proceedings, and provided that the documents are not shown on the
`screen in open PTAB proceedings, in the same way they were addressed in the district court
`litigation. Please confirm that you agree to these restrictions.
`
`Sincerely,
`Bill
`
`Bill Zimmerman
`Partner
`Bill.Zimmerman@knobbe.com
`202-640-6404 Direct
`Knobbe Martens
`1717 Pennsylvania Ave. N.W., Ste. 900
`Washington, D.C. 20006
`www.knobbe.com/bill-zimmerman
`
`
`
`From: Horniak, David <DHorniak@wc.com>
`Sent: Tuesday, October 22, 2019 10:00 AM
`To: Bill.Zimmerman <Bill.Zimmerman@knobbe.com>
`Subject: Narcan Nasal Spray -- IPR Request
`
`Hi Bill,
`
`Thanks for speaking with me yesterday. As you know, we represent Adapt Pharma in litigation
`involving the patents that cover Narcan® Nasal Spray. Last year, Indivior produced 12 documents in
`response to a subpoena in litigation between our client and Teva. A company called Nalox-1
`pharmaceuticals has now filed inter partes review petitions challenging Adapt’s patents, and the
`PTAB has instituted trial. See IPR2019-00685, IPR2019-00688, and IPR2019-00694. We would like
`Indivior’s permission to use a few of the documents it produced in the Teva case in the new inter
`partes review proceeding with Nalox-1.
`
`The documents we are seeking to use in the IPR are the same ones that Indivior authorized us to use
`at trial (and which we did use at trial) in the Teva matter. I have attached them again for your
`
`Opiant Exhibit 2178
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 2
`
`
`
`reference. If Indivior is amenable, we would be happy to request that the documents be submitted
`under seal subject to the PTAB’s form protective order.
`
`Please let me know if you have any questions, or if there is any other information I can provide that
`would be helpful. I look forward to hearing from you.
`
`Best,
`
`David
`
`
`David Horniak
`Williams & Connolly LLP
`725 Twelfth Street, N.W., Washington, DC 20005
`(P) 202-434-5852 | (F) 202-434-5029
`dhorniak@wc.com | www.wc.com/dhorniak
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is
`privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or
`disclose the contents of the message and any attachments. Instead, please delete the message and any attachments
`and notify the sender immediately. Thank you.
`
`
`NOTICE: This email message is for the sole use of the intended recipient(s) and may contain confidential and
`privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not
`the intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`
`NOTICE: This email message is for the sole use of the intended recipient(s) and may contain confidential and
`privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not
`the intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`
`Opiant Exhibit 2178
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 3
`
`